Drugs /

yttrium y 90-edotreotide

Back to Drugs List

Overview

Trade Name(s):
Onalta and Octreother
NCI Definition [1]:
A radioconjugate consisting of the octreotide derivative edotreotide labeled with yttrium 90 (Y-90) with potential radiotherapeutic uses. Similar to octreotide, yttrium Y 90-edotreotide binds to somatostatin receptors (SSTRs), especially type 2 receptors, present on the cell membranes of many types of neuroendocrine tumor cells, delivering tissue-specific, beta-emitting nuclide Y-90-mediated cytotoxicity to SSTR-positive cells. Yttrium Y 90-edotreotide is produced by substituting tyrosine for phenylalanine at the 3 position of the somatostatin analogue octreotide and chelating the substituted octreotide to Y-90 via dodecanetetraacetic acid (DOTA).

Clinical Trials

View Clinical Trials for yttrium y 90-edotreotide

Yttrium y 90-edotreotide has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating yttrium y 90-edotreotide, 1 is early phase 1 (1 open).

SSTR1 Expression, SSTR2 Expression, and SSTR3 Expression are the most frequent biomarker inclusion criteria for yttrium y 90-edotreotide clinical trials.

Neuroendocrine tumor is the most common disease being investigated in yttrium y 90-edotreotide clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Yttrium Y 90-Edotreotide
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating yttrium y 90-edotreotide and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
90y-dota-3-tyr-octreotide, edotreotide yttrium y-90, OctreoTher, Onalta, yttrium y 90 -dotatoc, yttrium y 90 smt 487, yttrium y 90-dota-3-tyrosine-octreotide, yttrium y 90-dota-tyr3-octreotide
Drug Target(s) [2]:
SSTR1, SSTR2, SSTR3, SSTR4, SSTR5
NCIT ID [1]:
C2601

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.